| 28th week of 2009 patent applcation highlights part 39 |
| Patent application number | Title | Published |
|---|
| 20090176656 | TISSUE REJECTION - This document relates to methods and materials involved in detecting tissue injury and/or rejection (e.g., injury and/or rejection of transplanted tissue). For example, this document relates to methods and materials involved in the early detection of kidney tissue injury. | 2009-07-09 |
| 20090176657 | BINDING AND FUNCTIONAL ASSAYS THAT USE THE T1R3 RECEPTOR TO SCREEN FOR TASTE MODULATORY COMPOUNDS - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed. | 2009-07-09 |
| 20090176658 | Real Time Binding Analysis of Antigens on a Biosensor Surface - The invention provides methods for detecting interactions between phage and antigen or antigen and antibody using biosensors. | 2009-07-09 |
| 20090176659 | TRANSCRIPTIONAL ENGINEERING OF LACTOBACILLUS - The invention relates to global transcription machinery engineering to produce altered cells having improved phenotypes and methods for evaluating phenotypic diversity. | 2009-07-09 |
| 20090176660 | Engineered Baculoviruses and Their Use - Baculovirus is engineered so that the capsid displays one or more heterologous peptides or protein. Such baculovirus can be used to deliver therapeutics, and in functional genomics. | 2009-07-09 |
| 20090176661 | WHOLE GENOME EXPRESSION ANALYSIS SYSTEM - A method for simultaneously determining a genetic expression profile for an individual member of a species relative to an entire standard genome for the species. The method can comprise distributing a liquid sample into an array of reaction chambers of a substrate. The array can comprise a primer set and a probe for each polynucleotide target along the entire standard genome. The liquid sample can comprise substantially all genetic material of the member. Each of the reaction chambers can comprise the primer set and the probe for at least one of the polynucleotide targets and a polymerase. The method can further comprise amplifying the liquid sample in the array, detecting a signal emitted by at least one of the probes, and identifying the genetic expression profile in response to the signal. | 2009-07-09 |
| 20090176662 | End Modification to Prevent Over-Representation of Fragments - The invention relates to a method of preparing a 5′ and 3′ modified library of template polynucleotides and also the use of the 5′ and 3′ modified library of templates in methods of solid-phase nucleic acid amplification. In particular, the invention relates to a method of preparing a 5′ and 3′ modified library of template polynucleotides which have common sequences at their 5′ ends and at their 3′ ends, wherein over-representation of “end” sequences of the primary polynucleotide molecules from whence the 5′ and 3′ modified library is generated is greatly reduced or prevented. | 2009-07-09 |
| 20090176663 | ARRAY PRINT BUFFERS - The present invention relates to compositions suitable for spotting compounds onto a substrate, and methods employing these compositions. The composition can include one or more organic anions of formula I: R(X) | 2009-07-09 |
| 20090176664 | High density peptide arrays containing kinase or phosphatase substrates - Peptide arrays and uses thereof for diagnostics, therapeutics and research. Ultra high density peptide arrays are generated using photolithography, such as using photoresist techniques. | 2009-07-09 |
| 20090176665 | Self-Degrading Fibers and Associated Methods of Use and Manufacture - This invention relates to the use of degradable fibers, and more particularly, to self-degrading fibers and their associated methods of use and manufacture. In one embodiment, the present invention provides a self degrading fiber comprising: an outer shell, and a core liquid. | 2009-07-09 |
| 20090176666 | Drilling Fluids Containing Biodegradable Organophilic Clay - Drilling fluids are provided that comprise an organophilic clay treated with a quaternary ammonium surfactant having an amide linkage. The quaternary ammonium surfactant may comprise a compound generally represented by the following formula: | 2009-07-09 |
| 20090176667 | Expandable particulates and methods of their use in subterranean formations - Methods are provided that include a method comprising providing a treatment fluid comprising at least a plurality of expandable particulates comprising a swellable elastomer composition. In some embodiments the expandable particulates may comprise a swellable elastomer and a filler material. In some embodiments the expandable particulates may comprise a solid particulate that has been at least partially coated with a swellable elastomer composition. In some embodiments, the treatment fluid may be placed into at least a portion of a subterranean formation at a pressure sufficient to create or enhance at least one fracture in the subterranean formation. Additional methods are also provided. | 2009-07-09 |
| 20090176668 | SEMI-SOLID LUBRICANT COMPOSITION FOR TRANSMISSION ELEMENT AND MECHANICAL SYSTEM PROVIDED WITH THE SAME - A semi-solid lubricant composition for transmission elements which is excellent in lubricity, antiwear properties, and energy-saving performance, has high reliability, and is for use as a turbine oil, machine tool oil, metal working oil, plastic working oil, cutting oil, compressor oil, vacuum-pump oil, electrical-contact oil, grease, or machine oil; and a mechanical system provided with the composition. The composition, which reduces the wear of sliding parts of a transmission element, comprises: an amide compound having one or two amide groups and forming a three-dimensional network structure; and a liquid base oil ingredient having a dynamic viscosity at 100° C. of 25 mm | 2009-07-09 |
| 20090176669 | LUBRICITY MAINTAINING IMAGE FORMING APPARATUS AND PROCESS CARTRIDGE - An image forming apparatus includes an image bearer that carries a toner image, and a lubricant supplying device that supplies lubricant to the surface of the image bearer. A lubricant supplying device is provided in the image forming apparatus and includes a lubricant block and a brush roller. The brush roller shaves and supplies the lubricant from the lubricant block to the image bearer via the brush roller. The lubricant is made by molding under pressure. | 2009-07-09 |
| 20090176670 | Biodegradable lubricating oil composition - [PROBLEMS] To provide a biodegradable lubricating oil composition which has excellent biodegradability, a high viscosity index, a low pour point, a high flash point, being satisfactory with lubricity, oxidative stability, property of preventing the corrosion of iron and non-ferrous metals, and suitability for use with sealing materials. | 2009-07-09 |
| 20090176671 | Grease Composition For Constant Velocity Joints - The present invention provides a grease composition for use in constant velocity joints, having improved wear resistance and endurance characteristics. | 2009-07-09 |
| 20090176672 | PREPARATION OF FUNCTIONAL MONOMERS FOR GRAFTING TO LOW MOLECULAR WEIGHT POLYALKENES AND THEIR USE IN THE PREPARATION OF DISPERSANTS AND LUBRICATING OIL COMPOSITIONS CONTAINING DISPERSANT POLYALKENES - A polyalkene dispersant comprised of low MW polyalkene having an average molecular weight range of about 300 to about 10,000 and an ethylenically-unsaturated, aliphatic or aromatic, nitrogen- and oxygen-containing graftable monomer and methods of making the same are disclosed. The monomers are formed by reacting an acylating agent with amines having one or more primary or secondary amine to form a reaction product. Graft polyalkene dispersants comprising such monomers are formed by grafting the reaction product to the polyalkene backbone. Also described is lubricating oil comprising base oil and the dispersant polyalkene as described above. | 2009-07-09 |
| 20090176673 | COLOR-CHANGING CLEANSING COMPOSITIONS AND METHODS - The present invention provides methods, kits and compositions that are nontoxic color changing cleansers The cleansers include a mixture having a first component mixture and a second component mixture, wherein the first component mixture comprises a nontoxic color changing dye and the first component mixture in combination with the second component mixture such that the color of the nontoxic color changing dye is of a different color than the nontoxic color changing dye in the first component mixture. | 2009-07-09 |
| 20090176674 | Personal care compositions containing cationic synthetic copolymer and a detersive surfactant - A personal care composition comprising:
| 2009-07-09 |
| 20090176675 | Personal Care Compositions Containing Cationically Modified Starch and an Anionic Surfactant System - Personal care compositions comprise (a) from about 0.01 wt. % to about 10 wt. % of a water-soluble cationically modified starch polymer, wherein said water-soluble cationically modified starch polymer has a molecular weight from about 850,000 to about 15,000,000 and a charge density from about 0.2 meq/g to about 5 meq/g; (b) from about 5 wt. % to about 50 wt. % of an anionic surfactant system, said anionic surfactant system comprising at least one anionic surfactant and having an ethoxylate level and an anion level, (i) wherein said ethoxylate level is from about 1 to about 6, and (ii) wherein said anion level is from about 1 to about 6; c) an effective amount of a pyrithione or a polyvalent metal salt of a pyrithione; d) an effective amount of a zinc-containing layered material; and (e) a cosmetically acceptable medium. Personal care compositions as described above further comprise from about 0.01 wt. % to about 10 wt. % of one or more oily conditioning agents. Methods of treating hair or skin comprise applying the personal care compositions as described above to the hair or skin and rinsing the hair or skin. | 2009-07-09 |
| 20090176676 | Conditioning Shampoo Containing Stabilized Silicone Particles - Shampoo compositions comprising a) a detersive surfactant, b) silicone particles, c) a protecting agent and d) an aqueous carrier provide superior conditioning. The silicone particles contain at least one amine functional silicone and optionally a non-amine functional silicone. | 2009-07-09 |
| 20090176677 | Treating liquid for photoresist removal, and method for treating substrate - Disclosed are a treating liquid for photoresist removal, containing (a) an oxidizing agent (e.g., aqueous hydrogen peroxide), (b) at least one selected from alkylene carbonates and their derivatives (e.g., propylene carbonate), and (c) water; and a method for treating with the treating liquid a substrate having a photoresist film deteriorated after dry-etching treatment thereof or a substrate optionally subjected to plasma-ashing treatment after the dry-etching treatment, and then treating it with a photoresist-stripping liquid for stripping off the photoresist. | 2009-07-09 |
| 20090176678 | SOLUTION AND METHOD FOR CLEANING AND RESTORATION OF HEADLIGHT LENSES - A cleaning solution for plastic headlight covers includes a saturation of crystallizable salts, such as ammonium sulfate or urea; an organic solvent, such as a terpene, glycol ether or alkyl alcohol; a buffered acid to maintain a pH between 3.0 and 5.5, such as citric acid, oxalic acid, sodium bisulfate, or boric acid; alumina nanoparticles of 0.05 micron size and other submicron sizes; as well as a sequestering (chelating) agent, surfactant, and hydrophilic combiner; all in an aqueous solution. The cleaning solution effectively removes the mineral solids from the crazed surface of a plastic headlight cover that form a base for accumulating organic residue and road grime. No abrasive scouring or recoating of the surface with an acrylic sealant is required. | 2009-07-09 |
| 20090176679 | Detergent Compositions - The present invention provides a laundry detergent composition, a process for making said composition, the use of the composition in a laundry detergent and a method for treating fabric with the composition. Said laundry detergent compositions | 2009-07-09 | |
| 20090176680 | USE OF A CELLULASE TO IMPART SOIL RELEASE BENEFITS TO COTTON DURING A SUBSEQUENT LAUNDERING PROCESS - The present invention relates to the use of a cellulase to impart soil release benefits to cotton during a subsequent laundering process. | 2009-07-09 |
| 20090176681 | Bleach composition and bleaching detergent composition - A bleach composition containing (a) a peroxide generating hydrogen peroxide by being dissolved in water, (b) a water-insoluble or poorly water-soluble textile powder selected from powder cellulose, silk powder, wool powder, nylon powder and polyurethane powder, and (c) (c-1) a bleaching activating catalyst and/or (c-2) a bleaching activator. | 2009-07-09 |
| 20090176682 | LAUNDRY DETERGENT COMPOSITION COMPRISING GLYCOSYL HYDROLASE - The present invention relates to a laundry detergent composition comprising glycosyl hydrolase. The compositions of the present invention also comprises a polymer that, when used in combination with the glycosyl hydrolase, enables compaction of the surfactant system to be achieved without loss in fabric cleaning performance. Preferably, the composition of the present invention comprises a combination of two polymers, a glycosyl hydrolase and detersive surfactant, preferably low levels of detersive surfactant. | 2009-07-09 |
| 20090176683 | EFFERVESCENT DETERGENT DISPENSER KIT AND METHOD - A kit and method for preparing a cleaning solution for delivery under pressure includes combining a cleaning composition, an oxidizing agent, an effervescent agent and an aqueous medium in a pressurizable container having an opening with a removably mounted cap. The effervescent agent reacts with the aqueous medium to generate a gas to pressurize the cleaning solution within the container. The method can be used for preparing a cleaning solution for use with a pressurizable container have an aerosol valve assembly or an extraction cleaner with a fluid delivery system for dispensing the cleaning solution under pressure to a surface to be cleaned. The cleaning solution and a pressurizable container having a removably mounted cap with an aerosol valve assembly can be provided as a kit to a consumer for preparing a pressurized cleaning solution. | 2009-07-09 |
| 20090176684 | Detergents having acceptable color - Detergent compositions containing catechols, such as tiron (1,2-dihydroxybenzene-3,5-disulfonic acid), which do not have or do not develop the reddish color associated with the catechol/ferric iron chelate are disclosed. Methods for reducing the intensity of red color in a tiron containing detergent composition are also disclosed. | 2009-07-09 |
| 20090176685 | CORROSION INHIBITING COMPOSITIONS - Corrosion inhibiting composition for use in aqueous or semi-aqueous stripping, cleaning, abrasive lapping and abrasive slurry compositions that form 5, 6, 7, or 8-membered chelating rings with a base metal together with a film forming polymeric chelation agent. Optionally there is included an oxygen scavenger. | 2009-07-09 |
| 20090176686 | STABILIZER FOR ORGANIC SOLVENTS - A stabilizer composition comprising a) an amine and b) a compound selected from aliphatic, non-cyclic monomeric polyunsaturated hydrocarbons and terpenes is useful for stabilizing an organic solvent against degradation. | 2009-07-09 |
| 20090176687 | SOLIDIFICATION MATRIX USING A POLYCARBOXYLIC ACID POLYMER - A solidification matrix includes a polycarboxylic acid polymer, sodium carbonate, and water. Exemplary polycarboxylic acid polymers include a polyacrylic acid polymer having a molecular weight of between about 1,000 and about 100,000, a modified polyacrylic acid polymer having a molecular weight of between about 1,000 and about 100,000, and a polymaleic acid polymer having a molecular weight of between about 500 and about 5,000. The polycarboxylic acid polymer, sodium carbonate, and water interact to form a hydrate solid. The solidification matrix may be used, for example, in a solid detergent composition. | 2009-07-09 |
| 20090176688 | SOLIDIFICATION MATRIX USING AN AMINOCARBOXYLATE - A solidification matrix includes a biodegradable aminocarboxylate, sodium carbonate, and water. The biodegradable aminocarboxylate, sodium carbonate, and water interact to form a hydrate solid. The solidification matrix may be used, for example, in a solid detergent composition. | 2009-07-09 |
| 20090176689 | Tetrafluoroborate compounds, compositions and related methods of use - Tetrafluoroboric acid and an organic nitrogenous base, related compounds and compositions, as can be used in conjunction with various methods of cleaning and/or the treatment of substrate surfaces. | 2009-07-09 |
| 20090176690 | Composition and Method of Increasing the Substantivity of a Fragrance - This invention relates to a composition and method of increasing the substantivity of a fragrance deposited on to a human substrate and to a fluid composition for use therein. | 2009-07-09 |
| 20090176691 | Pharmaceutical Compositions Containing at Least One Protein Active Ingredient Protected From Digestive Enzymes - The present invention relates to pharmaceutical compositions containing at least one protein active ingredient protected from digestive enzymes. Said pharmaceutical compositions contain said at least one protein active ingredient, in free form, as well as, for liquids, a system that buffers them to a pH greater than 4 and less than or equal to 8 or, for solids, a system that exerts, when they are placed in a liquid medium, a buffer effect between a pH greater than 4 and a pH less than or equal to 8. | 2009-07-09 |
| 20090176692 | AMIDATED INSULIN GLARGINE - The invention relates to insulin glargine which is modified by amidation, especially Gly (A21), Arg (B31), Arg amide (B32) human insulin (insulin glargine amide). | 2009-07-09 |
| 20090176693 | AGENT FOR MAINTAINING THE HARDNESS OF TOOTH STRUCTURE - Provided are an agent for maintaining hardness of tooth substances and a food or drink for maintaining the hardness of tooth substances, both of which include lactoferrin and iron-lactoferrin as an active ingredient. Lactoferrin and iron-lactoferrin suppress decalcification of enamel by use or ingestion thereof, and hence is effective for the prevention of dental caries. | 2009-07-09 |
| 20090176694 | Reagents and Methods for Smooth Muscle Therapies - The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration. | 2009-07-09 |
| 20090176695 | Reagents and Methods for Smooth Muscle Therapies - The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration. | 2009-07-09 |
| 20090176696 | Methods And Compositions For Modulating An Immune Response - The present invention provides compositions and methods for the suppression of Th2-mediated immune response. Tracheal cytotoxin is shown to mediate a selective suppression of T helper cell type 2 (Th2)-mediated immune responses. The methods and compositions of the invention are useful for the treatment of Th2-mediated diseases and conditions due to their utility in suppressing Th2-mediated immune responses. The invention further extends to methods for suppressing the production of cytokines, such as IL-4 and IL-5 which contribute to the development of Th2-mediated immune responses. | 2009-07-09 |
| 20090176697 | Method to obtain the human Chorionic Gonadotropin (hCG)/cyclodextrin complex for oral administration, product obtained by this method and clinical and therapeutic use of the complex human Chorionic Gonadotropin (hCG)/cyclodextrin - To inform about the clinical utility human Chorionic Gonadotropin (hCG) complexed with cyclodextrins for oral administration, its utility in different pathologies and method for obtaining it. | 2009-07-09 |
| 20090176698 | Benzimidazolone Derivatives for the Treatment of Urinary Incontinence - The invention relates to compositions comprising benzimidazolone derivatives of formula (I), optionally in form of the free base or in form of the pharmacologically acceptable acid addition salts thereof and methods of treating or preventing urinary incontinence, comprising the administration of a therapeutically effective amount of compound of formula (I), wherein R | 2009-07-09 |
| 20090176699 | Inhibitors Based on Fusion, Hr1 and Hr2 Sequences in Bacterial Adhesin - A known surface adhesin (NadA) in | 2009-07-09 |
| 20090176700 | Derivatives Of GLP-1 Analogs - The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant. | 2009-07-09 |
| 20090176701 | Anti-microbial agents that interact with the complement system - Anti-microbial therapeutic agents that act via a novel method to treat infection are compounds which may comprise a peptide with natural or non-natural amino acids, or a small molecule. The agent can bind to the surface of a microorganism and productively fix complement in order to cause lysis of the microorganism via the assembly of a membrane attack complex, thereby triggering removal of the microbe by phagocytosis. The agents may be fragments of TFPI e.g. from the C-terminus region. | 2009-07-09 |
| 20090176702 | USE OF LONG-ACTING RECOMBINANT HUMAN SOLUBLE TUMOR NECROSIS FACTOR ALPHA RECEPTOR IN MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF HEPATIC FAILURE - The present invention belongs to the field of the application of genetic engineering and gene function, and it is directed to a new medical use of the gene encoding the recombinant soluble tumor necrosis factor α receptor (HusTNFR). The present invention made intervention to fulminant hepatic failure in mice by use of the long-acting recombinant human soluble tumor necrosis factor α receptor and the classic animal models of acute and sub-acute hepatic failure. The results showed that the long-acting soluble tumor necrosis factor αreceptor of the present invention has a half-life extended more than 10 times, and it significantly decreased the mortality of model animals and has superior therapeutic effect for the treatment and/or prophylaxis of acute and sub-acute hepatic failure in model animals. These receptors have a noticeable therapeutic effect for the treatment and/or prophylaxis of acute and sub-acute hepatic failure in comparison with the non-long-acting HusTNFR. | 2009-07-09 |
| 20090176703 | NEUROPEPTIDES FOR AQUATIC ORGANISMS CULTURE - The present invention is related to the use of variants of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) to stimulate the growth and to improve the immunological system of aquatic organisms. The variants of the peptide were provided by immersion, injection or as a food additive. | 2009-07-09 |
| 20090176704 | Exendin Agonist Analogs to Treat Diabetes - Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 2009-07-09 |
| 20090176705 | MODULAR PLATFORM FOR TARGETED THERAPEUTIC DELIVERY - Pharmaceutical compounds, pharmaceutical compositions and methods of treatment are disclosed, wherein a compound comprises a targeting moiety which, in free form, binds a cell receptor with a dissociation constant K | 2009-07-09 |
| 20090176706 | MATERIALS AND METHODS FOR TREATMENT OF INFLAMMATORY AND CELL PROLIFERATION DISORDERS - The present invention pertains to methods for treatment of inflammatory and cell proliferation disorders, such as cancer, by administering an agent that reduces atrial natriuretic peptide receptor-A (NPR-A) activity. In one aspect, the invention concerns a method for treatment of inflammatory and cell proliferation disorders, such as cancer, by administration of an effective amount of natriuretic hormone peptide (NP), or a polynucleotide encoding NP and an operably-linked promoter sequence. In another aspect, the present invention includes a pharmaceutical composition comprising an agent that reduces the activity of atrial natriuretic peptide receptor-A (NPR-A), and an anti-cancer agent. In another aspect, the present invention further concerns a method for identifying an agent useful for treating an inflammatory or cell proliferation disorder, comprising determining whether the agent reduces the activity of atrial natriuretic peptide receptor-A (NPR-A). | 2009-07-09 |
| 20090176707 | HUMAN SIGNAL PEPTIDE-CONTAINING PROTEINS - The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP. | 2009-07-09 |
| 20090176708 | CHEMICALLY MODIFIED FACTOR IX - The present invention discloses a chemically modified FIX, wherein the activation peptide region contains a covalently coupled water-soluble hydrophilic polymer. | 2009-07-09 |
| 20090176709 | PROCESS FOR OBTAINING A CONCENTRATE OF VON WILLEBRAND FACTOR OR A COMPLEX OF FACTOR VIII/VON WILLEBRAND FACTOR AND USE OF THE SAME - The process is characterised by the preparation of a solution of Von Willebrand Factor or a complex of Factor VIII/Von Willebrand Factor which contains VWF and a concentration of up to 12 IU VWF:RCo/ml and a Von Willebrand Factor/Factor VIII ratio of 0.4 or more; and then proceeding with nanofiltration of the solution prepared in a) through a filter having a pore size of less than 35 nanometres. | 2009-07-09 |
| 20090176710 | COMPLEX FOR TRANSFERRING AN ANIONIC SUBSTANCE INTO A CELL - The present invention relates to compositions and methods for the delivery of an anionic substance using complexes, comprising the anionic substance and a peptide. These complexes are useful for delivering said anionic substance into a cell, particularly in therapeutic applications. | 2009-07-09 |
| 20090176711 | INHIBITORS OF AMYLOID PRECURSOR PROTEIN PROCESSING - Disclosed is a method of using a compound as an inhibitor for β-secretase, wherein the compound is capable of binding to the site within the β-secretase recognition and/or cleavage site on amyloid precursor protein to specifically inhibit the β-secretase's activity to cleave amyloid precursor protein with maintaining its activities to other substrates. Further, the present invention relates to inhibitors of amyloid precursor protein (APP) processing which bind to the site within the β-secretase or γ-secretase cleavage and/or recognition site on amyloid precursor protein. | 2009-07-09 |
| 20090176712 | Peptides with Efficacy in Rescuing Melanocortin-4 Receptor Polymorphic Agonist Signaling - Disclosed are novel ligands based on an AGRP template that can rescue endogenous melanocortin agonist and/or antagonist dysfunction at MCR polymorphisms. In particular, the present invention provides novel synthetic ligands based on AGRP templates that can rescue endogenous melanocortin agonist dysfunction at MC4R polymorphisms to treat children and adults with these mutations and increase their quality of life. | 2009-07-09 |
| 20090176713 | Co-Administration of an Agent Linked to an Internalization Peptide with an Anti-Inflammatory - The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension. | 2009-07-09 |
| 20090176714 | METHOD OF REDUCING THE EFFECTS OF ABeta AND COMPOSITIONS THEREFORE - The invention provides methods and materials related to inhibiting the effects of Aβ such as neuronal cell death and tau phosphorylation. For example, the invention provides polypeptides, compositions containing polypeptides, transgenic animals, and methods for preventing an Aβ effect (e.g., neuronal cell death in a mammal). | 2009-07-09 |
| 20090176715 | Pharmaceutical Compositions and Methods Utilizing a D-Amino Acid - The present invention provides a pharmaceutical composition for oral administration comprising a D-amino acid combined with an antioxidant selected from the group consisting of vitamin E, vitamin C, a glutathione or a precursor thereof. | 2009-07-09 |
| 20090176716 | INHIBITORS OF CANCER CELL, T-CELL AND KERATINOCYTE PROLIFERATION - The invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, | 2009-07-09 |
| 20090176717 | GALACTOSIDES AND THIODIGALACTOSIDES AS INHIBITORS OF PA-IL LECTIN FROM PSEUDOMONAS - Compositions and methods are provided related to | 2009-07-09 |
| 20090176718 | Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome - The present invention provides a pharmaceutical composition for the treatment of a disordered metabolism syndrome comprising anthocyanin-rich extracts from berries. The present invention further provides a method for treating a disordered metabolism syndrome utilizing anthocyanin-rich extracts from berries. | 2009-07-09 |
| 20090176719 | COMPOSITIONS AND METHODS FOR TREATING PERIORAL DERMATITIS - Methods for treating perioral dermatitis are described herein. The method includes administering topically a composition containing an effective amount of a systemic or topical antibiotic and a corticosteroid. The concentration of the antibiotic is from about 0.01% to about 5% by weight of the composition and the concentration of the corticosteroid is from about 0.01% to about 5% by weight of the composition. The composition can contain one or more pharmaceutically acceptable excipients and/or carriers. The compositions can be formulated as a lotion, cream, gel, ointment, paste, powder, solution, suspension, spray, foam, or patch. | 2009-07-09 |
| 20090176720 | COMPOSITIONS CONTAINING PIPERACILLIN AND TAZOBACTAM USEFUL FOR INJECTION - An aminocarboxylic acid chelating agent, preferably EDTA, or a salt thereof has been found to be useful for inhibiting particulate formation in piperacillin/tazobactam parenteral combinations. The composition may also contain a buffer, preferably citrate, and optionally an aminoglycoside. The product may be in the form of a frozen composition that can be thawed for use. The product may also be in the form of a cryodesiccated powder that can be reconstituted by addition of an aqueous vehicle to reform a solution. | 2009-07-09 |
| 20090176721 | NUCLEOSIDE ANALOGS WITH CARBOXAMIDINE MODIFIED MONOCYCLIC BASE - Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity. | 2009-07-09 |
| 20090176722 | Androgen-regulated PMEPA1 gene and polypeptides - This invention relates to the androgen-regulated gene, PMEPA1, and proteins encoded by this gene, including variants and analogs thereof. Also provided are other androgen-regulated nucleic acids, a polynucleotide array containing these androgen-regulated nucleic acids, and methods of using the polynucleotide array in the diagnosis and prognosis of prostate cancer. | 2009-07-09 |
| 20090176723 | Methods and compositions involving miRNA and miRNA inhibitor molecules - The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays. | 2009-07-09 |
| 20090176724 | Methods and Compositions for the Diagnosis, Prognosis and Treatment of Cancer - The invention is relates to splice variants of basal transcription factors and other transcriptional modulators, the use of expression analyses of the same as a diagnostic and prognostic tool, and the targeting of such splice variants for therapeutic purposes, particularly in relation to the treatment of cancer. | 2009-07-09 |
| 20090176725 | CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID MOLECULES THAT MEDIATE RNA INTERFERENCE - The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, and others that can inhibit the function of endogenous RNA molecules, such as endogenous micro-RNA (miRNA) (e.g., miRNA inhibitors) or endogenous short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC), including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules and are useful, for example, in providing compositions to prevent, inhibit, or reduce diseases, traits and conditions that are associated with gene expression or activity in a subject or organism. | 2009-07-09 |
| 20090176726 | METHODS FOR TREATING MITF-RELATED DISORDERS - Methods for treating melanoma and other MITF-related disorders by administering a compound that causes an increase in HIF-1 level or activity (e.g., by increasing the level of HIF-1I in a cell) within cells. Such methods include administration of a compound that is a hydroxylase inhibitor, e.g., a prolyl hydroxylase inhibitor that reduces hydroxylation of HIF-1I thereby causing an increase in HIF-1I in the cell. Such treatment can lead to a decrease in MITF activity or expression. | 2009-07-09 |
| 20090176727 | DOUBLE-STRANDED RNA STRUCTURES AND CONSTRUCTS, AND METHODS FOR GENERATING AND USING THE SAME - The present invention relates to novel double-stranded RNA (dsRNA) structures and dsRNA expression constructs, methods for generating them, and methods of utilizing them for silencing genes. Desirably, these methods specifically inhibit the expression of one or more target genes in a cell or animal (e.g., a mammal such as a human) without inducing toxicity. These methods can be used to prevent or treat a disease or infection by silencing a gene associated with the disease or infection. The invention also provides methods for identifying nucleic acid sequences that modulate a detectable phenotype, such as the function of a cell, the expression of a gene, or the biological activity of a target polypeptide. | 2009-07-09 |
| 20090176728 | Treatment of CNS Conditions - Methods and compositions for the treatment of pathologic conditions of the central nervous system (CNS) by means of intranasal administration of a composition that modulates, by means of RNA interference, the expression and/or activity of genes involved in above-mentioned conditions. | 2009-07-09 |
| 20090176729 | METHOD OF TREATING NEURODEGENERATIVE DISEASE - Aspects featured in the invention relate to compositions and methods for inhibiting alpha-synuclein (SNCA) gene expression, such as for the treatment of neurodegenerative disorders. An anti-SNCA agent featured herein that targets the SNCA gene can have been modified to alter distribution in favor of neural cells. | 2009-07-09 |
| 20090176730 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS - The present invention is directed to a method and composition of treating or preventing viral infections, in particular, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts, comprising the administration of N.sup.4-acyl-2′,3′-dideoxy-5-fluorocytidine or N.sup.4-acyl-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine, and pharmaceutically acceptable salts, prodrugs, and other derivatives thereof. | 2009-07-09 |
| 20090176731 | COMBINATION THERAPY OF CANCER WITH AZD2171 AND GEMCITABINE - The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in combination with gemcitabine; to a pharmaceutical composition comprising AZD2171 and gemcitabine; to a combination product comprising AZD2171 and gemcitabine for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and gemcitabine; to the use of AZD2171 and gemcitabine in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation. | 2009-07-09 |
| 20090176732 | PROTECTED NUCLEOTIDE ANALOGS - Disclosed herein are nucleotide analogs with one or more protecting groups, methods of synthesizing nucleotide analogs with one or more protecting groups and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with the nucleotide analogs with one or more protecting groups. | 2009-07-09 |
| 20090176733 | Novel Medicaments for Anti-Herpes Virus Treatments - The invention concerns the use of a sulphated or phosphated polysaccharide for preparing a drug for treating herpes virus mediated diseases, more particularly mediated by alpha-herpes viruses, and in particular by HSV-1 and HSV-2, as well as by strains of those viruses which are resistant to known antiviral agents. The polysaccharide is preferably sulphated laminarin PS3. | 2009-07-09 |
| 20090176734 | Method For Simulating The Functional Attributes Of Human Milk Oligosaccharides In Formula-Fed Infants - The present invention is directed to a novel method for increasing the production of acetate, decreasing the production of butyrate, increasing the population and species of beneficial bacteria and slowing the rate of fermentation of prebiotics within the gut of a formula-fed infant. The method comprises administration of a therapeutically effective amount of PDX to the infant. | 2009-07-09 |
| 20090176735 | PREVENTING OR REDUCING OXIDATIVE STRESS OR OXIDATIVE CELL INJURY - A water-soluble cellulose derivative is useful for preventing or reducing oxidative stress or oxidative cell injury in tissues of an animal and in particular for regulating Stearoyl-CoA Desaturase-1 gene expression and/or ATPF1 gene expression in non-adipose tissues of the animal. | 2009-07-09 |
| 20090176736 | PHARMACEUTICAL COMPOSITION FOR CONFORMATIONAL DISEASES - A pharmaceutical composition is provided which is prophylactically and/or therapeutically effective for a conformational disease typified by Alzheimer's disease, prion disease, and amyloidosis. The pharmaceutical composition of the present invention includes as an active ingredient one or more cellulose ethers selected from a cellulose ether having a structural unit represented by the general formula (1): | 2009-07-09 |
| 20090176737 | Composition for Soft Contact Lens and Adsorption Suppressing Method - Disclosed is a composition for soft contact lenses which enables to suppress adsorption of a basic chemical substance onto a soft contact lens. This composition for soft contact lenses comprises (A) a basic chemical substance selected from amines having a secondary amino group and/or a tertiary amino group and salts thereof, and (B) one or more substances selected from amino acids and salts thereof, acid mucopolysaccharides and salts thereof and cyclodextrin, while having a pH of 3.5 to 4.8. Also disclosed is a method for suppressing adsorption of the basic chemical substance onto a soft contact lens. | 2009-07-09 |
| 20090176738 | Dermal medicament delivery system - There is provided a means of applying a heated medicament to the skin and concurrently hydrating the skin thus raising the efficacy of administration. | 2009-07-09 |
| 20090176739 | OPTICAL ISOMERS OF AN ILOPERIDONE METABOLITE - The present invention relates to novel isomers of a metabolite of Iloperidone, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them. | 2009-07-09 |
| 20090176740 | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine - Aniracetam (1-[(4-methoxybenzoyl)]-2-pyrrolidinone) is co-administered with the acetylcholine precursor 1-alpha glycerylphosphorylcholine (Alpha GPC, choline alfoscerate, choline alphoscerate) to potentiate cognition enhancing effects in healthy subjects and patients suffering from neurological conditions including Alzheimer's Disease (AD), attention deficit disorder (ADD), Parkinson's Disease, schizophrenia, vascular dementia, post stroke aphasia, anxiety disorders, cerebral atrophy, chronic alcoholism, Down syndrome, dyslexia, and various other neurodegenerative conditions. The co-administration of aniracetam (and other racetam derivatives including oxiracetam) with the acetylcholine precursor 1-alpha glycerylphosphorylcholine decreases negative side-effects such as severe headaches while increasing the synthesis and release of the neurotransmitters acetylcholine and glutamate to facilitate proper brain functioning. | 2009-07-09 |
| 20090176741 | MODULATION OF THE IMMUNE SYSTEM BY INOSITOL PHOSPHOLIPIDS - The invention relates to the field of immunology. More specifically, it relates to methods and compositions to suppress the immune system, among other by interference with antigen-presenting molecules and T-cell activation. Provided is a composition for the prevention or treatment of a condition wherein suppression of T cell activation is desirable, comprising as an active ingredient an inositol phospholipid or a pharmaceutically acceptable salt thereof. Said condition can be an auto-immune disease, allergic disorder or chronic inflammatory disease, for example asthma, diabetes Type I, rheumatoid arthritis (RA) or inflammatory bowel disease (IBD). Also provided is a food item or food supplement having immunomodulating properties, comprising an effective amount of an inositol phospholipid. | 2009-07-09 |
| 20090176742 | METHODS RELATING TO THE TREATMENT OF FIBROTIC DISORDERS - The invention provides α-mimetic structure of formula (I), wherein A is —(C═O)—(CHR | 2009-07-09 |
| 20090176743 | Methods for treating or preventing reactivation of a latent herpesvirus infection - The invention is directed to methods and compositions for treating or preventing reactivation of a latent herpesvirus infection and the associated complications and outcomes. The methods involve administering a composition comprising glutamine, or a derivative, conjugate, or analog thereof. | 2009-07-09 |
| 20090176744 | Deuterated fingolimod - This invention relates to novel compounds that are deuterated derivatives of fingolimod and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering a lysophospholipid edg1 (S1P1) receptor agonist, such as fingolimod. | 2009-07-09 |
| 20090176745 | TRIARYLMETHANE ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are triphenyl methane analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, inflammatory, degenerative and vascular diseases, including various ocular diseases, and parasitic infections. Representative triphenyl methane analogs include triphenyl methane analogues of various dyes, hormones, sugars, peptides, oligonucleotides, amino acids, nucleotides, nucleosides, and polyols. The compounds are believed to function by inhibiting tNOX expression, the effects of ROS, and/or the production of HIF2. Thus, the compounds are novel therapeutic agents for a variety of cancers and other diseases. | 2009-07-09 |
| 20090176746 | THROMBOPOIETIN MIMETICS - Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy-1-azobenzene derivative. | 2009-07-09 |
| 20090176747 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT - The instant invention is directed towards tetracycline compositions, and methods of inhibiting Tdp1 activity, and methods of treating Tdp1-associated disorders. | 2009-07-09 |
| 20090176748 | METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE ORAL DOSAGE OF A VITAMIN D COMPOUND - A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation. | 2009-07-09 |
| 20090176749 | OIL-IN-WATER EMULSION LOTION CONTAINING 22-OXA-1ALPHA, 25-DIHYDROXYVITAMIN D3 AND METHOD OF TREATMENT OF SKIN DISORDER USING THE SAME - Provided is a lotion that exhibits high percutaneous absorption inherent in maxacalcitol, allows the maxacalcitol to be stable, and exhibits less dripping when it is applied to heads. A basic oil-in-water emulsion lotion containing 22-oxa-1α,25-dihydroxyvitamin D | 2009-07-09 |
| 20090176750 | Compositions and methods for enhancing corticosteroid delivery - The present invention comprises a composition, method of enhancing potency and method of delivering corticosteroids in a vehicle comprising at least two penetration enhancers, and solvents and emulsifiers. The propylene glycol and penetration enhancers are present in ratio to the total of the propylene glycol, penetration enhancers, and solvents and emulsifiers of at least about 0.70. | 2009-07-09 |
| 20090176751 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS - A combination which comprises (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid. | 2009-07-09 |
| 20090176752 | Diene Compounds and Formulations - The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus, for example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it has been discovered that compounds of the invention are useful in the prevention and treatment of androgen-independent cancers such as androgen-independent prostrate cancer. Finally, inventive compounds may be used to treat antiandrogen induced withdrawal syndrome. | 2009-07-09 |
| 20090176753 | Betulinol derivatives as anti-cancer agents - The present invention relates to a method of treating cancer selected from the group of cancers consisting of prostate cancer, renal cancer, breast cancer, ovarian cancer, CNS cancer, melanoma, lung cancer, and bladder cancer. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a betulinol derivative compound of Formula (I). Also disclosed are conjugated and immunoconjugated derivatives of the compound of Formula (I) as well as methods of making and using them. | 2009-07-09 |
| 20090176754 | Crystalline Form of the Compound A-348441 - There is provided a hemihydrate of (3β, 5β, 7α, 12α)-7,12-dihydroxy-3-{2-[{4-[17β-hydroxy-3-oxo-17α-prop-1-ynylestra-4,9-dien-11β-yl]phenyl}(methyl)amino]ethoxy}cholan-24-oic acid in a crystalline form which is characterised by an X-ray diffraction pattern having major peaks at 2θ=6.58±0.2, 8.54+0.2, 12.28±0.2, and 19.68±0.2. This crystalline material is useful in the treatment of conditions associated with an excess of hepatic glucocorticoid response. | 2009-07-09 |
| 20090176755 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTIBIOTIC - The present invention relates to cefdinir. More particularly to pharmaceutical formulations comprising cefdinir in a defined polymorphic form and processes for the preparation thereof. Furthermore, the present invention relates to processes to keep cefdinir in a defined polymorphic form. | 2009-07-09 |
